BOTHELL, WA and VANCOUVER, BC, Feb. 7, 2012 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, Chief Executive Officer, will provide a corporate presentation at the following investor conferences:
- BIO CEO & Investor Conference on Tuesday, February 14 at 8:30 a.m. ET at the Waldorf Astoria Hotel in New York City
- Leerink Swann Global Healthcare Conference on Wednesday, February 15 at 11:30 a.m. ET at the Waldorf Astoria Hotel in New York City
- Citi Global Health Care Conference on Tuesday, February 28 at 4 p.m. ET at the Waldorf Astoria Hotel in New York City
- RBC Capital Markets Global Healthcare Conference on Wednesday, February 29 at 8:00 a.m. ET at the New York Palace Hotel in New York City
- Cowen Annual Health Care Conference on Monday, March 5 at 1:30 p.m. ET at the Boston Marriott Copley Place in Boston
Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. Webcast replays will be archived for 90 days.
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that subsequent studies may not confirm earlier trial results, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Quarterly Report on Form 10-Q for third quarter ended September 30, 2011. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
For further information: